OTCMKTS:AXIM - Axim Biotechnologies Stock Price, News, & Analysis

-0.06 (-7.49 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
Now: $0.7416
50-Day Range
MA: $0.84
52-Week Range
Now: $0.7416
Volume99,833 shs
Average Volume146,950 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical, and cosmetic products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. Axim Biotechnologies, Inc. was formerly known as Axim International Inc. and changed its name to Axim Biotechnologies, Inc. in July 2014. The company was founded in 2010 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:AXIM



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive AXIM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXIM and its competitors with MarketBeat's FREE daily newsletter.

Axim Biotechnologies (OTCMKTS:AXIM) Frequently Asked Questions

What is Axim Biotechnologies' stock symbol?

Axim Biotechnologies trades on the OTCMKTS under the ticker symbol "AXIM."

Has Axim Biotechnologies been receiving favorable news coverage?

Media coverage about AXIM stock has trended very negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axim Biotechnologies earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Axim Biotechnologies.

Who are some of Axim Biotechnologies' key competitors?

What other stocks do shareholders of Axim Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axim Biotechnologies investors own include Cronos Group (CRON), OrganiGram (OGI), Insys Therapeutics (INSY), Aphria (APHA), Canopy Growth (CGC), CannTrust (CNTTF), Curaleaf (CURLF), CV Sciences (CVSI), Charlotte's Web (CWBHF) and Emerald Health Therapeutics (EMHTF).

Who are Axim Biotechnologies' key executives?

Axim Biotechnologies' management team includes the folowing people:
  • Dr. George E. Anastassov, Founder & Chairman (Age 56)
  • Mr. John W. Huemoeller II, CEO & Director (Age 64)
  • Mr. Robert T. Malasek, CFO & Sec. (Age 51)
  • Mr. Lekhram Changoer, CTO & Director (Age 52)
  • Dr. Philip A. Van Damme D.M.D., M.D., DMD, MD, Ph.D., Chief Medical Officer & Director (Age 66)

How do I buy shares of Axim Biotechnologies?

Shares of AXIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axim Biotechnologies' stock price today?

One share of AXIM stock can currently be purchased for approximately $0.7416.

What is Axim Biotechnologies' official website?

The official website for Axim Biotechnologies is http://aximbiotech.com/.

How can I contact Axim Biotechnologies?

The company can be reached via phone at 212-751-0001.

MarketBeat Community Rating for Axim Biotechnologies (OTCMKTS AXIM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  20
MarketBeat's community ratings are surveys of what our community members think about Axim Biotechnologies and other stocks. Vote "Outperform" if you believe AXIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Featured Article: Market Perform

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel